Thermal Cures in the Treatment of Multiple Sclerosis
Thermal Cures in the Treatment of Multiple Sclerosis: Effectiveness on the Quality of Life
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Spa therapy
What it measured
Main measures
Benefit of spa treatment on quality of life assessed by the scale SEP-59
within 15 weeks after inclusion
Physical functionPainQuality of life (reported by participants)
Other measures (5)
Benefit of a spa treatment based on average number of steps per day for one week assessed by actimeter
9 weeks after inclusion
Physical functionBenefit of a thermal cure based on treatment consumption of hospital and ambulatory care
15 to 17 weeks after inclusion
Benefit of a thermal cure based on depression and anxiety assessed by the scale Hospital Anxiety and depression scale
15 to 17 weeks after inclusion
PainMood and sleepBenefit of a thermal cure based on tiredness assesed by the fatigue impact scale
15 to 17 weeks after inclusion
FatiguePainBenefit of a thermal cure regarding pain assessed by the scale DN 4
15 to 17 weeks after inclusion
Pain
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Patient with primary or progressive secondary-phase MS * Showing EDSS \<7 severity criteria * Patient with MS for whom an indication of spa treatment has been made, * Patient agreeing to participate in this study and therefore accepting the constraints related to the design "immediate cure-deferred cure", * Patient receiving the general social security scheme, * Patient having given written consent to participate in the study
Exclusion criteria
* Patient does not meet the inclusion criteria, * Patient with relapsing remitting MS * Patient unfit according to the investigator to complete the rating scales * Patient with heat intolerance called "Uhthoff effect" * Patient with a contraindication to the spa treatment: urinary or faecal leakage, wound, thrombophlebitis less than three months old, unstabilized cardio respiratory disease. * Patient with serious life-threatening condition (ie, cancer) * Patient under tutorship or curatorship * Patient participating in another interventional clinical research project
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Multiple Sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, with significant public health consequences. The benefit of spa treatments on the quality of life in this population has not been evaluated. The methods of study in clinical pharmacology can be a scientific methodological model for the evaluation of thermal practices and it is in this perspective that investigators want to lead this project.
Loading reviews and guidelines…
History
Started
May 2019
Main results due
May 2021
Finished
Aug 2021